Newly Diagnosed Myeloma

Authored by Vincent Rajkumar, published on 2026-07-18 10:55:26.0

Treatment algorithm for newly diagnosed myeloma patients.  Dr. Rajkumar is a contributing editor to the International Myeloma Foundation (https://www.myeloma.org/frontline-treatment-options).

  1. Standard Risk
    • Dara-VRd or Isa-VRd
      • Standard-risk post-ASCT maintenance
        Use lenalidomide for 2 years. If daratumumab + lenalidomide maintenance is selected, continue daratumumab until progression and lenalidomide for 2 years. For standard-risk disease after early ASCT: - Use lenalidomide maintenance for 2 years. - If daratumumab + lenalidomide maintenance is selected: - Continue lenalidomide for 2 years. - Continue daratumumab until disease progression or unacceptable toxicity. - Individualize treatment according to response, MRD status, tolerability, infection risk, cytopenias, renal function, patient preference, access, and prior anti-CD38 exposure. - Monitor CBC, renal function, thromboembolic risk, infections, rash, diarrhea, fatigue, and secondary primary malignancies. - Do not extrapolate the daratumumab duration automatically to isatuximab-containing maintenance; follow the selected protocol and available evidence.
        • Len or Len plus Anti-CD38 (Dara/lsa) maintenance
      • Len or Lenalidomide plus Anti-CD38 (Dara/Isa) maintenance
  2. High Risk
    • Standard-risk maintenance without upfront ASCT
      Use lenalidomide for 2 years. If daratumumab + lenalidomide is selected, continue daratumumab until progression and lenalidomide for 2 years. For standard-risk patients not undergoing upfront ASCT: - Use lenalidomide maintenance for 2 years. - If daratumumab + lenalidomide is selected: - Continue lenalidomide for 2 years. - Continue daratumumab until disease progression or unacceptable toxicity. - Reduce or discontinue dexamethasone after the initial treatment phase when clinically appropriate. - Individualize therapy according to frailty, renal function, infection risk, cytopenias, quality of life, patient preference, and treatment tolerance.
      • Early ASCT if eligible
        • High-risk doublet maintenance
          Use lenalidomide plus a proteasome inhibitor or anti-CD38 therapy. Continue lenalidomide for 2 years; if daratumumab is selected, continue daratumumab until progression. For high-risk disease after ASCT: - Use doublet maintenance with lenalidomide plus a proteasome inhibitor or anti-CD38 therapy. - Continue lenalidomide for 2 years. - If daratumumab + lenalidomide is selected: - Continue lenalidomide for 2 years. - Continue daratumumab until disease progression or unacceptable toxicity. - If proteasome inhibitor-based maintenance is selected, determine its duration according to the specific regimen, cytogenetic risk, response, tolerability, neuropathy, and institutional protocol. - Do not automatically apply the daratumumab duration to isatuximab-containing maintenance. - Reassess response, MRD status, cytopenias, infection burden, neuropathy, renal function, and treatment tolerance.
tosprivacyDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaIsatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaKumar S, Jacobus S, Cohen A, et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2026;395:221-232. doi:10.1056/NEJMoa2600157.Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaLenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma